首页> 外文期刊>International Journal of Pharmaceutical Sciences and Research >TERBINAFINE INCORPORATED SODIUM HYALURONATE MICROSPHERE MUCO-ADHESIVE SYSTEM FOR VAGINAL CANDIDIASIS
【24h】

TERBINAFINE INCORPORATED SODIUM HYALURONATE MICROSPHERE MUCO-ADHESIVE SYSTEM FOR VAGINAL CANDIDIASIS

机译:特比萘芬掺入透明质酸钠微球粘液治疗念珠菌性阴道病

获取原文
           

摘要

The aim of the present investigation was to prepare and evaluate novel bioadhesive vaginal microspheres containing Terbinafine (TBH) in order to provide long-term therapeutic activity at the site of infection and prove the same using in vitro anti fungal activity of the same using Candida albicans. Microspheres were prepared by the Solvent extraction technique using sodium hyaluronate and Arlacel A. Microspheres were characterized by SEM, DSC, FTIR, particle size analysis and evaluated for percentage yield, drug loading, encapsulation efficiency and in vitro drug release. FTIR and DSC studies showed that no chemical changes or alterations occurred in the drug and polymers. The sphericity factor indicated that the prepared microspheres were spherical. Formulation (TBHMs) indicated a controlled in vitro drug release and good bioadhesive strength. The in vitro anti fungal activity confirmed for a controlled and prolonged capacity of the prepared novel formulation. The results indicated that this drug delivery system can be explored for controlled intra-vaginal drug release.
机译:本研究的目的是制备和评估含有特比萘芬(TBH)的新型生物粘附性阴道微球,以便在感染部位提供长期治疗活性,并使用白色念珠菌对其进行体外抗真菌活性的验证。 。通过使用透明质酸钠和Arlacel A的溶剂萃取技术制备微球。通过SEM,DSC,FTIR,粒度分析对微球进行表征,并评估收率,载药量,包封效率和体外药物释放。 FTIR和DSC研究表明,药物和聚合物中没有发生化学变化或改变。球形度表明所制备的微球是球形的。制剂(TBHM)表明体外药物释放受控,并且具有良好的生物粘附强度。体外抗真菌活性证实了所制备的新型制剂具有受控和延长的能力。结果表明,该药物递送系统可用于控制阴道内药物释放。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号